Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2001-2-9
pubmed:abstractText
To determine the outcomes of women with isolated loco-regional recurrence (LRR) of breast cancer treated with high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) following conventional therapy, we conducted a retrospective review of 58 patients from five institutions treated between 1990 and 1998. Forty-five patients (78%) had > or = 2 poor prognostic factors (PPF) (defined as disease-free interval preceding LRR < or = 2 years, hormone receptor negative/refractory disease, and incomplete resection). At median follow-up of 14.2 (0.5-72) months, 36 patients (62%) developed progressive disease. Disease progression usually occurred at local (27 patients) vs distant (nine patients) sites. Median time to disease progression following ASCT was 6.1 (1.3-31.4) months. At last follow-up, 23 patients (40%) had expired (all due to disease progression), and 13 (22%) were alive with, and 22 (38%) without progressive disease. By Kaplan-Meier analysis, the estimated median PFS and OS was 20.3 and 29.2 months, respectively. In a multivariate model, complete remission at time of HDCT and estrogen-receptor positive disease were predictive of significantly longer PFS and OS. The survival of this cohort was similar to previous reports of those treated with conventional therapy alone, and to those with distant metastases treated with HDCT. Frequent progression locally, suggests that strategies to improve local disease control are needed.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
947-53
pubmed:dateRevised
2006-4-24
pubmed:meshHeading
pubmed-meshheading:11100273-Adult, pubmed-meshheading:11100273-Aged, pubmed-meshheading:11100273-Antineoplastic Agents, Hormonal, pubmed-meshheading:11100273-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11100273-Breast Neoplasms, pubmed-meshheading:11100273-Chemotherapy, Adjuvant, pubmed-meshheading:11100273-Combined Modality Therapy, pubmed-meshheading:11100273-Disease Progression, pubmed-meshheading:11100273-Female, pubmed-meshheading:11100273-Follow-Up Studies, pubmed-meshheading:11100273-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11100273-Humans, pubmed-meshheading:11100273-Life Tables, pubmed-meshheading:11100273-Mastectomy, pubmed-meshheading:11100273-Middle Aged, pubmed-meshheading:11100273-Neoplasm Proteins, pubmed-meshheading:11100273-Neoplasm Recurrence, Local, pubmed-meshheading:11100273-Neoplasms, Hormone-Dependent, pubmed-meshheading:11100273-Prognosis, pubmed-meshheading:11100273-Radiotherapy, Adjuvant, pubmed-meshheading:11100273-Receptors, Estrogen, pubmed-meshheading:11100273-Remission Induction, pubmed-meshheading:11100273-Retrospective Studies, pubmed-meshheading:11100273-Survival Analysis, pubmed-meshheading:11100273-Treatment Outcome, pubmed-meshheading:11100273-Tumor Markers, Biological
pubmed:year
2000
pubmed:articleTitle
Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation.
pubmed:affiliation
Washington University School of Medicine, Division of Bone Marrow Transplantation and Stem Cell Biology, St Louis, MO 63110-1093, USA.
pubmed:publicationType
Journal Article, Review, Multicenter Study, Evaluation Studies